White Paper

Retrofit Pharmaceutical Equipment For High Containment And Reduced Risk Of Cross Contamination

Source: ILC Dover

By Scott Patterson, Vice President Technical Support and Paulo Bento, Field Application Specialist


With the growth of highly potent active pharmaceutical ingredients (HPAPIs) and multiple-use facilities that must protect against product cross contamination, the need for engineering controls to achieve high containment has become more critical. Technology has evolved over the past 20 years to meet reduced exposure levels while also making high-containment systems financially reasonable. Not so along there was a mindset in pharmaceutical processing that containment systems came at a significant capital cost, and handling HPAPIs resulted in an even higher CapEx for the proper controls. This does not need to be the case with the implementation of single-use or flexible containment technology. In this paper we explore how single-use containment technology impacts capital spending and operating expenses in these workflows.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Pharmaceutical Online